Viewing nowCombinationLinadip Duo Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 202400569 · Approved 2024.03.18 · Insurance code 670609320
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes who need to take both Linagliptin and Metformin in controlling their blood sugar levels. Taking this medication along with dietary control and exercise therapy is effective for blood sugar management. Consistent treatment helps maintain stable blood sugar levels and can aid in the prevention of diabetes-related complications. This medication is used to improve blood sugar control in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.
This medication is a drug that helps control blood sugar levels. While rare, a serious condition called lactic acidosis can occur during treatment, so caution is needed. Especially, patients with allergies to any of the components included in this medication, those with type 1 diabetes, severe renal impairment, liver dysfunction, acute infections, or dehydration should not take this medication. Additionally, patients with cardiac-related diseases such as acute myocardial infarction or severe heart failure or those who are pregnant should not use this medication. Risk of hypoglycemia exists, so when used with other anti-diabetic agents or insulin, blood sugar levels should be monitored frequently, and doses may need to be adjusted as necessary. For elderly patients with renal function decline or those taking medications that may affect the kidneys, kidney function should be regularly checked. This medication should be swallowed whole and not chewed or crushed; the tablet shell may be excreted in the stool, which is normal. If symptoms such as abdominal pain, muscle weakness, breathing difficulties, severe skin rashes, or blistering skin conditions occur during treatment, consult a doctor immediately. It is recommended not to use this medication during pregnancy and lactation, and patients planning to conceive or who are pregnant should consult with their doctor. Also, this medication may interact with other drugs, so it is imperative to inform healthcare professionals before starting any new medication. Regular blood tests and physical examinations to check for adverse reactions while taking this medication are important. If an overdose occurs, seek medical attention immediately for appropriate treatment, and urgent care is needed, especially if symptoms of lactic acidosis arise. Finally, this medication should be kept out of the reach of children and stored away from moisture.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Ideally, maintain a storage temperature between 1 and 30 degrees Celsius.
Yellow, oval-shaped, bilayered extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.